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Abstract The aim of the study was to assess the corre-
lation of the results of the treatment of infratentorial
ependymomas with the degree of resection and histopath-
ological diagnosis. The study was conducted on a group
of 19 patients, 13 boys and 6 girls aged 3 months to
16 years, with infratentorial ependymoma treated at the
Department of Paediatric Neurosurgery of the Medical
University of Silesia in Katowice from January 2000
until December 2008. The most significant factor having
an impact on overall survival and progression-free sur-
vival was totality of tumour resection. There has been no
statistically significant influence of the histopathological
type of ependymoma on the result of treatment. The ten-
dency to report better results of treatment of non-
anaplastic ependymoma seems to derive from a statisti-
cally higher frequency of total removal of tumours of
this type.
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Introduction
Ependymoma is a neoplasm of the central nervous system that
arises from ependymal cells that line the ventricles of the brain
and the centre of the spinal cord. Intramedullary, spinal cord
ependymomas occur more frequent in adults than in children,
whereas the highest rate of occurrence of intracranial
ependymomas has been noted in patients aged less than 20.
Along with medulloblastoma and pilocytic astrocytoma, intra-
cranial ependymoma is the most frequent primary tumour of
the primary nervous system. It has been estimated that the fre-
quency of occurrence of intracranial ependymoma amounts to
6–10 % of all intracranial tumours [1, 2]. Being located in the
fourth brain ventricle, intracranial ependymomas are usually
infratentorial and constitute one of the most frequent tumours
of the posterior cranial fossa. WHO grading of ependymal tu-
mours includes the following types of ependymomas:
ependymomas (cellular ependymoma, papillary ependymoma,
clear cell ependymoma, tanycytic ependymoma) graded WHO
II, anaplastic ependymomas graded WHO III, and
myxopapillary ependymomas and subependymomas graded
WHO I. The selection of optimised treatment of ependymomas,
especially in the case of treatment of children, involves a lot of
controversy and varies from medical centre to medical centre.
The treatment involves surgical removal of the tumour, radia-
tion therapy and chemotherapy [1–3].
The aim of the study
The aim of the study was to assess the correlation of the results
of the treatment of infratentorial ependymomas with the de-
gree of resection and histopathological diagnosis.
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Material and methods
The study was conducted on a group of 19 patients with
infratentorial ependymoma treated at the Department of Pae-
diatric Neurosurgery, Medical University of Silesia in Kato-
wice from January 2000 to December 2008. Firstly, the med-
ical documentation of 360 patients treated for intracranial tu-
mours was subject to retrospective analysis. Out of these pa-
tients, a group of 19 patients with infratentorial ependymoma
was selected, including 13 boys and 6 girls aged 3 months to
16 years. Secondly, the medical documentation was analysed
with regard to gender, age and types of applied treatment with
a special focus on the degree of resection, histopathological
diagnosis, progression-free survival (PFS) and overall surviv-
al (OS). The degree of tumour resection was assessed on the
basis of the MRI examination performed 6 weeks after the
surgery. Lack of features of tumour residue was taken as the
criterion of total resection of the tumour. Progression-free sur-
vival (PFS) was defined as the period from diagnosis to re-
ported progression, recurrence of the disease or death. Overall
survival (OS) was defined as the period from diagnosis to
death of any cause. In order to assess progression-free survival
and overall survival, the Kaplan-Meier method was applied.
Log-rank test was applied to analyse progression-free survival
and overall survival with regard to histopathological type and
degree of tumour resection. The results were statistically
analysed by means of a specialist software Statistica PL v
6.0, and the level of significance assumed was α≤0.05.
Results
Among 140 patients with posterior cranial fossa tumours that
were treated at the Department of Paediatric Neurosurgery in
Katowice, there were 19 (12.8 %) cases of infratentorial
ependymoma. Infratentorial ependymoma was diagnosed in
13 (68.4 %) boys and 6 (31.6 %) girls. The relation of young
male patients to young female patients was 2.16. The age of
the children at the moment of diagnosis varied from 3 months
to 16 years. Five children were younger than 4 when their
disease was diagnosed. All of the children were subject to
surgical treatment. Total resection was achieved in 11
(57.9 %) patients, whereas subtotal resection in 7 (36.8 %)
patients. One patient (5.2 %) was subject to tumour biopsy.
Five patients were subject to second surgery due to tumour
recurrence: Three children were operated twice, one child was
operated three times and also one child was operated five
times. Histopathological examination resulted in a diagnosis
of anaplastic ependymoma in 11 (57.9 %) patients. Moreover,
ependymoma was diagnosed in 8 (42.1 %) patients. In 6
(31.6 %) children older than 4 with diagnosed anaplastic
ependymoma and reported tumour residue or tumour progres-
sion, radiation therapy was applied. In nine (47 %) children
with diagnosed anaplastic ependymoma and reported tumour
residue or tumour progression, chemotherapy was applied.
The time of observation varied from 3 to 113 months
(40.2 months in average). Tumour progression or tumour re-
currence was noted in eight (42.1%) patients within the period
of 3 to 60 months. The average time until progression or
recurrence amounted to 25.8 months. There were eight
(42.1 %) patients who died after an average time of 37 months
(from 6 to 90 months), one of them (12.5 %) with diagnosed
ependymoma and seven of them (87.5 %) with diagnosed
anaplastic ependymoma. All deaths were pronounced in a
group of patients with subtotal resection. Progression-free sur-
vival (PFS) and overall survival (OS) were assessed in the
group of patients, which are illustrated in Figs. 1 and 2.
It has been reported that the totality of tumour resection is
an independent and positive factor having an impact on PFS
and OS. This is illustrated in Figs. 3 and 4. The progression of
the disease was observed in two children who underwent total
tumour resection (respectively 8 and 43months after surgery).
No deaths were pronounced in the group of patients with total
resection during observation.
In the assessment of the correlation of PFS and OSwith the
histopathological type of tumour, no statistically significant
influence of the histopathological type of ependymoma on
the results of the treatment has been noted (Figs. 5 and 6).
It has been noted that the treatment is more effective in the
case of ependymoma grade II. Only one patient with
ependymoma grade II died, while there were seven deaths in
the group of anaplastic ependymoma. On the other hand, how-
ever, the total tumour resection was obtained in seven of eight
patients with ependymoma, while in the group of anaplastic
ependymoma, only in 4 of 11 cases. Better results of the treat-
ment of non-anaplastic ependymoma seem to derive from the
fact that such ependymoma was more frequently completely
removed (Fig. 7).
Discussion
Intracranial ependymomas are the most frequent primary tu-
mours of the central nervous system in children. These tu-
mours are characterised by uncertain prognosis, and the types
of treatment vary from centre to centre. In our study,
infratentorial intracranial ependymoma constituted 13 % of
all treated tumours of the posterior cranial fossa. They were
most frequent in boys, and the average age of patients when
the disease had been diagnosed was 7.7. Surgical treatment is
the basic method of treatment of ependymoma. All children
treated for ependymoma at the Department of Paediatric Neu-
rosurgery in Katowice were subject to a surgery. In more than
half of the children (58 %), total resection was performed,
while in almost 37 %, resection was subtotal, and in 5 %,
biopsy was selected as treatment. It is generally known that













Fig. 1 Progression-free survival
(PFS) in the group of patients













Fig. 2 Overall survival (OS) in
the group of patients involved in
the study















Fig. 3 Progression-free survival
(PFS) and the degree of tumour
resection in the group of patients
involved in the study. GTR gross
















Fig. 4 Overall survival (OS) and
the degree of tumour resection in
the group of patients involved in
the study. GTR gross tumour
resection, PR partial resection















Fig. 5 Progression-free survival
(PFS) and histopathological
diagnosis in the group of patients
involved in the study—log-rank
















Fig. 6 Overall survival (OS) and
histopathological diagnosis in the
group of patients involved in the
study—log-rank test p=0.11713.
E ependymoma, AE anaplastic
ependymoma
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one of the most significant factors influencing prognosis in
patients with primary ependymoma is the degree of resection.
It is also in our study that the totality of tumour resection
proved to be an independent factor that influenced
progression-free survival and overall survival in a positive
way. Similarly, the observation carried out by Phi et al. [4]
revealed significantly longer PFS in the group of children
who underwent total resection of the tumour (P=0.029).The
analysis of 182 cases of ependymoma treatment available in
medical literature by Cage et al. [1] resulted in a similar con-
clusion. In patients after total tumour resection, the longest
period of PFS and OS was noted independently of location
of the tumour and its histopathological type. In contrast to this,
subtotal tumour resection involved higher mortality rate that
was minimised by additional radiation therapy in the case of
ependymoma graded WHO III [1]. Similarly in our study, all
deaths were pronounced in a group of patients who had been
subject to subtotal resection. It should be added that radiation
therapy was applied in six (31.6 %) children older than 4 with
diagnosed anaplastic ependymoma and reported tumour resi-
due or progression. This procedure was conducted in compli-
ance with the BStandardised and Modified Programme of Di-
agnostics and Treatment of Tumours of the Central Nervous
System in Children^ recommended by the Polish Paediatric
Solid Tumour Group. The role of chemotherapy has been an-
other broadly discussed issue with regard to the treatment of
ependymoma. Chemotherapy has been suggested to decrease
tumour mass, increase resectability and to avoid the necessity
of application of radiation therapy in infants [4]. In our study
based on the guidelines of the BStandardised and Modified
Programme of Diagnostics and Treatment of Tumours of the
Central Nervous System in Children,^ chemotherapy was ap-
plied in nine (47 %) children older than 4 with diagnosed
anaplastic ependymoma and reported tumour residue or tu-
mour progression. In the treatment of ependymoma, especially
recurring ependymoma, stereotactic radiosurgery is additional-
ly applied after resection and conventional radiation therapy.
Kano et al. [5] reported that, with regard to ependymoma of
small size, the effectiveness of recurrence or progression treat-
ment was increased owing to the application of stereotactic
radiosurgery. A more positive response to treatment involving
stereotactic radiosurgery was also observed in children with a
late disease recurrence [6]. In spite of the development of al-
ternative methods of treatment of ependymoma, such as che-
motherapy, conventional radiation therapy and stereotactic ra-
diosurgery, surgical treatment is still the basis of treatment
procedures both in primary and recurrent tumour [2]. In the
group of 19 patients treated for ependymoma at the Depart-
ment of Paediatric Neurosurgery in Katowice, tumour recur-
rence was noted in 40 % (eight) of patients after an average
25.5-month period. Out of this group of eight children, five



















diagnosis and the degree of
tumour resection in the group of
patients involved in the study—
Pearson’s chi-squared test
p<0.005. GTR gross tumour
resection, PR partial resection, E
ependymoma, AE anaplastic
ependymoma
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been reported by Vinchon et al. [2], who diagnosed recurrence
in 33 out of 70 patients (47 %) treated for intracranial
ependymoma, where 18 patients were subject to another sur-
gery. Taking into account a 5-year period of time, the survival
rate in the group of patients after secondary surgery amounted
to 38%, whereas in the case of patients after total resection, the
survival rate was as high as 58 %. From the statistical perspec-
tive, OS in patients with tumour recurrence was significantly
longer in patients after surgical treatment. Moreover, a longer
OS was noted in patients who were subject to total resection
during the second surgery. That perioperative mortality was
lower in the case of second surgery than in the case of the first
surgery that seems to be an interesting observation. Another
intriguing point is that, in spite of the decrease in body condi-
tion caused by scars remaining after the primary surgery and
radiation therapy after it, the period of hospital stay was shorter
after second surgery than after the first surgery. Such observa-
tions may result from a lower tumour mass and/or a better
preparation of the patient for the second surgery [2]. It was
also in the study by Zacharouilis et al. [7] that better prognosis
in the treatment of recurrent ependymomas was noted in a
group of patients after gross total resection. A significantly
longer time of overall survival was reported in a group of
patients subjected to gross total resection than in patients after
subtotal resection (44 vs. 23 %). However, no correlation of
histopathological type of tumour and the results of treatment
were reported with regard to both primary tumour—and recur-
rent tumour surgery [2, 3, 8]. In our study, the correlation of
PFS and overall survival (OS) with histopathologial type of the
tumour was analysed. However, no statistically significant in-
fluence of the histopathologial type of the tumour on the result
of treatment was noted. Similarly, in a retrospective analysis of
histopathological tests in 66 children who were subject to sur-
gical treatment of ependymoma, Gerszten et al. [8] did not find
any histopathological parameter that might have a prognostic
value.What they reported was only that necrosis, nuclear pleo-
morphism and proliferation of blood vessels in tumour tissue
correlate with a shorter PFS. This correlation, however, was
not statistically significant [8]. A similar observation was made
by Pollack et al. [3], who reported that both dissemination of
tumour cells and the presence of anaplastic features, such as
high mitotic index, did not have influence on the outcome.
Such factors as degree of tumour resection, age of the child
and the period of occurrence of symptoms until diagnosis, on
the contrary, had a prognostic value. Nevertheless, in our study,
better results of treatment of non-anaplastic ependymomawere
reported, which may derive from significantly higher frequen-
cy of total removal of tumours of this type. What is more, an
insufficient or non-representative tumour specimen and/or not
standardised criteria of histological assessment applied in dif-
ferent medical centres are additional factors that may indepen-
dently decrease prognostic value of the histopathological test
[9]. To add to this, it needs to be pointed out that some studies
reported a correlation of the histopathological character of tu-
mour with treatment [9]. For example, Phi et al. [4], in their
multivariate analysis of 33 children with infratentorial
ependymoma, showed that the shorter PFS correlated with
anaplastic histology of the tumour (P=0.004), a higher mitotic
counts (P=0.001) and a higher Ki-67 index (P=0.004). In the
course of treatment of ependymomas, genetic aberrations oc-
curring in tumour cells may also function as prognostic factors.
Korshunov et al. [9] based their study on gene expression
profiles and classified the analysed cases of ependymoma with
regard to location of the tumour, progression rate and age of the
patient. In their research based on the analysis of the genetic
profile, they also identified genes correlating with better prog-
nosis. Homozygous deletion of the gene CDKN2A as well as
chromosome 1q duplication constituted the best independent
indicators of unfavourable prognosis, whereas duplication of
chromosomes 9, 18 and 15q, and chromosome 6 deletion in-
dicated favourable prognosis [9, 10]. Another independent
prognostic factor is human telomerase reverse transcriptase
(hTERT) expression. Having based their assessment on immu-
nohistochemical tests, Tabori et al. [10] evaluated hTERT ex-
pression in a group of 65 patients who were subject to surgery
in order to treat ependymoma. A 5-year PFSwas noted in 57%
of hTERT-negative patients and 21 % of hTERT-positive pa-
tients. As far as 5-year OS is concerned, it was reported in 84
and 41 % of patients respectively. Both confirmed the prog-
nostic value of hTERT expression [11]. Wani et al. [12] eval-
uated the genetic profile of 56 patients treated for infratentorial
ependymoma. Two groups of patients were taken into consid-
eration: short recurrence-free survivors (PFS shorter than
3 years) and long recurrence-free survivors (PFS longer than
three years). The aim of the study was to develop a clinical test
for the routine assessment of patients diagnosed with
ependymoma. The analysis resulted in selecting a 10-gene sig-
nature which was an independent predictor of PFS. The au-
thors demonstrated also that a shorter survival time was asso-
ciated with increased expression of genes associated with an-
giogenesis and proliferation [13]. Genetic markers added to
usually applied clinical and histopathological prognostic fac-
tors may result in easier prognosis in the treatment of
ependymoma. Unfortunately, an important factor hindering
the common use of molecular prognostic tests is their high
cost.
Conclusion
1. The most significant factor having an impact on overall
survival and progression-free survival is totality of tumour
resection.
2. There has been no statistically significant influence of the
histopathological type of ependymoma on the result of
treatment.
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3. The tendency to report better outcome of non-anaplastic
ependymoma seems to derive from a statistically higher
frequency of total removal of tumours of this type.
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